INVO Bioscience Expands its Training Capacity

INVO Bioscience Expands its Training Capacity

MEDFORD, Mass., March 13, 2018 /PRNewswire/ -- INVO Bioscience, Inc. (OTC: IVOB), a medical device company granted FDA clearance for the first Intravaginal Culture System, INVOcell(TM), today announced the expansion of its certified training locations for Reproductive Endocrinologists and Embryologists to learn about the unique techniques of the simplified INVOcell Procedure. The two new centers will be in San Antonio, Texas and South Carolina. The addition of these two centers brings the total number of certified training locations for the INVOcell procedure to three.

The certified INVO training center has become a critically important function in the expansion of the INVOcell device and procedure. To this point, all training for the more than 60 reproductive endocrinologists and embryologists has occurred in Dallas, Texas at The Center for Assisted Reproduction (CARE). Under the direction of INVO Bioscience's medical director, Dr. Kevin Doody, participants undergo an intensive training and educational workshop on the INVOcell device and procedure. The seminar includes a full review of the procedure, stimulation through implantation of the embryos. This interactive session includes a couple of hours of hands on loading of the INVOcell device with the eggs, sperm and culture media. Lengthy discussions along with questions and answers flow throughout the couple of days.

As the utilization of INVOcell has grown, and the number of locations utilizing the device and procedures has grown, the expansion of certified training locations has been required. INVO Bioscience has worked with two of its most high profile users of the technology, Dr. Francisco Arredondo of RMA of Texas in San Antonio, and Dr. John Nichols of Piedmont Reproductive Endocrinology Group (PREG) in South Carolina, to replicate the training procedures to accelerate the number of individuals that can be trained.

Katie Karloff, Chair and Chief Executive Officer of INVO Bioscience, commented, "Dr. Arredondo and his team at RMA of Texas along with Dr. Tony Anderson of Embryo Director and Dr. John Nichols and his team at PREG have shown their commitment to expanding fertility care in their areas and reaching patients who could not afford current reproductive services. They share in our belief that INVOcell can revolutionize the fertility industry. By utilizing the women's own body as an incubator, it decreases the number of office visits, blood work, monitoring and other costs associated with traditional in vitro fertilization (IVF). These decreased costs translate into an approximate 50% reduction in the overall cost per cycle for patients. Despite the decreased costs, pregnancy rates with INVOcell are equivalent to that of traditional IVF."

The Company is continuing to work with other doctors who too have shown outstanding results to possibly add additional training locations, allowing for the reduction of travel time for future practices who would like to offer the INVO procedure at their clinics.

About The Center for Assisted Reproduction (CARE)
The Center for Assisted Reproduction, established in 1989, has been a pioneer of assisted reproductive technologies in the north Texas region with several firsts including the first ICSI pregnancy and the first to successfully implement a blastocyst culture system. CARE Fertility had the first pregnancy in the region with a pregnancy following embryo biopsy and pre-implantation genetic testing for cystic fibrosis. CARE Fertility/ Effortless IVF also was the first to adopt the INVOcell(TM) Intravaginal Culture System since the INVOcell first obtained FDA clearance. Dr. Doody is President of the Society for Assisted Reproductive Technology (SART), on the Board of Directors of the American Society for Reproductive Medicine (ASRM) and a member of the RESOLVE Physician Council. For more information, please visit https://www.embryo.net/

About RMA of Texas
RMA of Texas is a leading provider of fertility-based solutions with multiple locations in Texas is under the direction of Dr. Francisco Arredondo, MD, a respected and experienced board certified reproductive endocrinologist, who has published numerous papers on infertility. In 2017, Dr. Arredondo expanded his focus to the opening of the United States' first fertility center to exclusively offer the INVOcell device and solution to patients - Smart IVF. The Smart IVF center will offer INVOcell's patented medical device that enables egg fertilization and early embryo development to take place in the woman's body, in vivo. For more information, please visit http://www.rmatx.com/

About Embryo Director
Dr. Tony Anderson, PhD and his team are a leading provider of clinical embryology, consulting and hands on embryology training. With more than 20,000 In Vitro Fertilization cycles and nearly 30 years' experience, Anderson continues to lead the laboratory in success rates that exceed the national average as reported to the CDC and SART every year. Dr. Anderson is also the multi-site lab director for RMA of Texas and consultant to some of the top IVF centers in the US. Dr. Anderson has been an early adopter and pioneering research and application of blastocyst embryo transfer, cryopreservation and biopsy for genetic testing. For more information, please visit http://www.embryodirector.com/

About Piedmont Reproductive Endocrinology Group (PREG)
Piedmont Reproductive Endocrinology Group (PREG), with four locations throughout South and North Carolina, has received local and national attention for being leaders in the field of reproductive medicine. Founded in 2003 by Dr. John Nichols, PREG is a private infertility clinic consistently recognized nationally for their exceptional pregnancy success rates. PREG now has six in-house physicians - Dr. John Nichols, Dr. John Payne, Dr. James Holman, Dr. Travis McCoy, Dr. Edward Tarnawa and Dr. Gail Whitman-Elia - who specialize in advanced infertility treatments. Headquartered in Greenville, South Carolina, PREG's nearly 7,000 square-foot facility contains a Surgical Suite, accredited by the American Association of Ambulatory Surgical Facilities, as well as In Vitro Fertilization, Andrology, and Endocrine laboratories. Their practice is the only one in the Southeast with two IVF labs as well as two surgery centers since they obtained Advanced Fertility Institute in Columbia, South Carolina in 2016. For more information, please visit http://www.pregonline.com/

About INVO Bioscience
We are a medical device company focused on creating simplified, lower cost treatments for patients diagnosed with infertility. Our solution, the INVO Procedure, is a disruptive new technology. The INVO Procedure is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. Our lead product, the INVOcell, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (ART). The INVOcell is the first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (IVF) and Intrauterine Insemination (IUI). Our mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase availability of care. For more information, please visit http://invobioscience.com/

Safe Harbor Statement

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

INVO Bioscience, Inc.

Katie Karloff, CEO
978-878-9505 ext. 504
kkarloff@invobio.com

View original content with multimedia:http://www.prnewswire.com/news-releases/invo-bioscience-expands-its-training-capacity-300612772.html

SOURCE INVO Bioscience, Inc.